Published in Diabet Med on January 01, 2006
A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet (2014) 1.16
Clinical experience with insulin glargine in type 1 diabetes. Diabetes Technol Ther (2010) 0.89
The evolution of insulin glargine and its continuing contribution to diabetes care. Drugs (2014) 0.88
Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. Core Evid (2007) 0.80
Modern basal insulin analogs: An incomplete story. Indian J Endocrinol Metab (2014) 0.75
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia (2008) 4.62
Intensive attention improves glycaemic control in insulin-dependent diabetes without further advantage from home blood glucose monitoring: results of a controlled trial. Br Med J (Clin Res Ed) (1982) 1.61
Effect of high dose inhaled beclomethasone dipropionate on carbohydrate and lipid metabolism in normal subjects. Thorax (1987) 1.48
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab (2015) 1.47
Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion. Diabetologia (1982) 1.46
A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes. Diabetes Res Clin Pract (2011) 1.44
The UK Diabetes Dataset: a standard for information exchange. Diabetes Audit Working Group of the Research Unit of the Royal College of Physicians. British Diabetic Association. Diabet Med (1995) 1.42
Diabetes care in general practice: an approach to audit of process and outcome. Br J Gen Pract (1993) 1.40
A fifteen-month double-blind cross-over study of the efficacy and antigenicity of human and pork insulins. Diabet Med (1984) 1.37
Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia (1987) 1.36
Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med (2006) 1.33
Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption. Br Med J (Clin Res Ed) (1981) 1.32
Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med (2002) 1.20
Diagnostic confusion in diabetes with persistence of fetal haemoglobin. BMJ (1992) 1.20
A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract (2010) 1.10
Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast. Br Med J (Clin Res Ed) (1983) 1.09
A dataset to allow exchange of information for monitoring continuing diabetes care. The Diabetes Audit Working Group. Diabet Med (1993) 1.08
Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. Diabetes Obes Metab (2012) 1.00
Diagnosing the undiagnosed with diabetes. BMJ (1994) 1.00
Prevalence of morning hyperglycaemia: determinants of fasting blood glucose concentrations in insulin-treated diabetics. Diabet Med (1985) 0.99
Measurement of free insulin concentrations: the influence of the timing of extraction of insulin antibodies. Diabetologia (1985) 0.99
Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med (2006) 0.99
A crossover comparison of continuous subcutaneous insulin infusion (CSII) against multiple insulin injections in insulin-dependent diabetic subjects: improved control with CSII. Diabetes Care (1984) 0.99
Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabet Med (2013) 0.98
Human insulin. Clin Endocrinol Metab (1982) 0.98
A laboratory trial of two new blood-glucose reflectance meters featuring automatic external calibration. Ann Clin Biochem (1984) 0.97
Identifying the impact of diabetes research. Diabet Med (2006) 0.97
Morphology of palpably abnormal injection sites and effects on absorption of isophane(NPH) insulin. Diabet Med (1990) 0.96
Friedewald equation underestimates low-density lipoprotein cholesterol at low concentrations in young people with and without Type 1 diabetes. Diabet Med (2010) 0.96
Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. Hepatology (1991) 0.96
Plasma free insulin profiles after administration of insulin by jet and conventional syringe injection. Diabetes Care (1982) 0.95
A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes. Diabetes Obes Metab (2013) 0.94
Continuous subcutaneous insulin infusion versus injection therapy: a randomized cross-over trial under usual diabetic clinic conditions. Diabet Med (1988) 0.92
In vivo regulation of liver and skeletal muscle glycogen synthase activity by glucose and insulin. Diabetes (1986) 0.92
Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab (2004) 0.92
A comparison of the activity and disposal of semi-synthetic human insulin and porcine insulin in normal man by the glucose clamp technique. Diabetologia (1982) 0.92
Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens. Diabetes Care (1989) 0.89
The metabolic and hormonal response to acute normoglycaemia in type 1 (insulin-dependent) diabetes: studies with a glucose controlled insulin infusion system (artificial endocrine pancreas). Diabetologia (1982) 0.89
The new insulins. Their characteristics and clinical indications. Drugs (1982) 0.88
Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. Diabet Med (1990) 0.88
Insulin injection site tissue depths and localization of a simulated insulin bolus using a novel air contrast ultrasonographic technique in insulin treated diabetic subjects. Diabet Med (1992) 0.86
Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin. Exp Clin Endocrinol Diabetes (2007) 0.86
Comparative study of subcutaneous, intramuscular, and intravenous administration of human insulin. Lancet (1981) 0.85
Phrenic neuropathy in association with diabetes. Diabet Med (1992) 0.85
Forearm muscle metabolism in primary hypothyroidism. Eur J Clin Invest (1993) 0.84
Insulin insensitivity and skeletal muscle enzyme activities in response to overinsulinization in the rat. Metabolism (1987) 0.83
The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes. Diabetes Res Clin Pract (2005) 0.83
Problems and safety of continuous subcutaneous insulin infusion. Diabet Med (1984) 0.83
A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. Diabet Med (2003) 0.83
Comparison of portal and peripheral insulin delivery on carbohydrate metabolism in streptozotocin-diabetic rats. Diabetologia (1985) 0.83
Insulin glargine: the first clinically useful extended-action insulin analogue. Expert Opin Pharmacother (2001) 0.82
An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes. Diabetes Obes Metab (2009) 0.82
Human insulin: study of safety and efficacy in man. Br Med J (Clin Res Ed) (1981) 0.82
Muscle enzyme activity and insulin sensitivity in type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1986) 0.82
The measurement of metabolite exchange across muscle beds. Baillieres Clin Endocrinol Metab (1987) 0.82
Liver and muscle insulin sensitivity, glycogen concentration and glycogen synthase activity in a rat model of non-insulin-dependent diabetes. Diabetologia (1988) 0.81
Insulin sensitivity in hyperthyroidism: measurement by the glucose clamp technique. Clin Endocrinol (Oxf) (1983) 0.81
Repeatability of measurements and sources of variability in tests of cardiovascular autonomic function. Br Heart J (1992) 0.80
The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol (Oxf) (1996) 0.80
The effect of intraperitoneal insulin delivery on carbohydrate metabolism in type 1 (insulin-dependent) diabetic patients. Diabetes Res Clin Pract (1992) 0.80
Total-body potassium in insulin-dependent diabetes mellitus. Clin Sci (Lond) (1990) 0.80
A comparison of the pharmacokinetics and metabolic effects of human regular and NPH insulin mixtures. Diabetes Res Clin Pract (1991) 0.79
Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial. Diabet Med (2007) 0.79
The performance of three measures of health status in an outpatient diabetes population. Diabet Med (1993) 0.79
Night-time metabolic changes in normal subjects in the absence of the dawn phenomenon. Diabete Metab (1989) 0.79
Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. Pituitary (2000) 0.79
A survey of lower limb amputation in diabetic patients. Diabet Med (1992) 0.79
Metabolic handling of orally administered glucose in cirrhosis. J Clin Invest (1993) 0.78
The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients. Diabetes Care (1998) 0.78
Twenty-four hour C-peptide and insulin secretion rates and diurnal profiles of glucose, lipids and intermediary metabolites in cirrhosis. Clin Sci (Lond) (1992) 0.78
Comparison of the activity and pharmacokinetics of porcine insulin and human insulin (Novo) as assessed by the glucose clamp technique in normal and diabetic man. Diabetes Care (1983) 0.78
A comparison of 3 methods for assessing insulin sensitivity in subjects with normal and abnormal glucose tolerance. Diabetes Res (1985) 0.78
Free insulin levels and metabolic effects of meal-time bolus and square-wave intraperitoneal insulin infusion in insulin-dependent diabetic patients. Diabetologia (1985) 0.77
The effect of the optimal use of rapid-acting insulin analogues on insulin secretion in Type 2 diabetes. Diabetes Res Clin Pract (2006) 0.77
A comparison of human ultralente- and lente-based twice-daily injection regimens. Diabet Med (1989) 0.77
Continuous subcutaneous insulin infusion: comparison of plasma insulin profiles after infusion or bolus injection of the mealtime dose. Metabolism (1981) 0.77
Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins. Diabet Med (2009) 0.77
The effect of portal and peripheral insulin delivery on carbohydrate and lipid metabolism in a miniature pig model of human IDDM. Diabetologia (1997) 0.76
The effects of human proinsulin on glucose turnover and intermediary metabolism. Metabolism (1991) 0.76
Glycosylated haemoglobin in cord blood following normal and diabetic pregnancies. Diabetologia (1983) 0.76
Hepatic glycogen metabolism and insulin receptor status after long-term peripheral insulin delivery in the islet-transplanted diabetic rat. Diabetes (1986) 0.76
Bioavailability of highly purified bovine ultralente insulin. Diabetes Care (1983) 0.76
Observations on blood lipid and intermediary metabolite concentrations during conventional insulin treatment or CSII. Diabetes (1985) 0.76
Are reflectance meters necessary for home blood glucose monitoring? Br Med J (Clin Res Ed) (1981) 0.75
Cost-effectiveness of CSII. Diabet Med (2006) 0.75
Targets for glycated haemoglobin. Glycated haemoglobin targets are attainable. BMJ (1995) 0.75
The response of blood intermediary metabolite levels to 24 hours treatment with a blood glucose-controlled insulin infusion system in type 1 diabetes. Diabetes Res (1984) 0.75
Appointments and turnover of consultants and senior registrars in diabetes and endocrinology in the UK, 1984 and 1985. Diabet Med (1987) 0.75
Intermediary metabolism, insulin sensitivity and insulin receptor status under comparable long-term therapy with insulin injections and continuous subcutaneous insulin infusion. Acta Endocrinol (Copenh) (1988) 0.75
Hormonal and metabolic responses in brittle diabetic patients during feedback intravenous insulin infusion. Diabetes Res Clin Pract (1987) 0.75
Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. Diabetes Care (1998) 0.75
Lipid metabolism in rat models of causes of hyperinsulinaemia in insulin treated man. Diabete Metab (1987) 0.75
The changeover to U100 insulin in the United Kingdom. Neth J Med (1987) 0.75
Very low density lipoprotein metabolism after insulin over-treatment and during a euglycaemic clamp. Eur J Clin Invest (1987) 0.75